Published in Biotech Business Week, January 10th, 2005
Benefits were seen whether anastrozole was given as a primary treatment for 5 years, or as an additional treatment after 2 years of tamoxifen.
Aromatase inhibitors deplete circulating estrogen in postmenopausal women, shutting down the principal cell signaling pathway in the pathogenesis of breast cancer. Tamoxifen, in comparison, exerts its effect by interacting with the estrogen receptor.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.